{"product_id":"us-and-europe-metastases-spinal-tumor-market-research-report-forecast-to-2030","title":"US and Europe Metastases Spinal Tumor Market Research Report Forecast to 2030","description":"\u003cp\u003eUS and Europe Metastases Spinal Tumor Market Research Report Forecast to 2030\u003cbr\u003e\nThe growth of the US and Europe metastases spinal tumor market is attributed to the increasing incidences of metastases spinal tumor and the launch of the research start-up programme. However, the side effects associated with spine tumor treatments are anticipated to hamper the market growth.\u003c\/p\u003e\n\n\u003cp\u003eMetastatic spinal tumors are abnormal tissue clusters that can develop in the spine or adjacent to the spinal cord. More than 95% of metastatic spinal tumors are found extradural or within the vertebral body, and more than 50% of the time, they are found on multiple levels of the spine. These types of cancer are also referred to as secondary spinal tumors or spinal metastases. Moreover, primary spinal tumors are tumors that begin in the spinal column. They are quite rare, mostly benign (noncancerous), and make up a minor portion of spinal tumors.\u003c\/p\u003e\n\n\u003cp\u003eThe increasing incidences of metastases spinal tumor and the launch of the research start-up programme are imperative factors driving the growth of the US and European metastases spinal tumor market. However, the side effects associated with spine tumor treatment are restraining the growth of the US and Europe metastases spinal tumor market. Nonetheless, it is anticipated that ongoing clinical trials will create lucrative opportunities for the players operating in the US and Europe metastases spinal tumor market.\u003c\/p\u003e\n\n\u003cp\u003eMarket Segmentation\u003cbr\u003e\nBased on type, the US and Europe Metastases Spinal Tumor Market have been segmented into extradural, intradural-extramedullary, and intramedullary.\u003c\/p\u003e\n\n\u003cp\u003eBased on Diagnosis \u0026amp; Treatment, the US and Europe metastases spinal tumor market has segmented diagnosis, and treatment. The treatment segment dominated the market in 2022 and the diagnosis segment is projected to be the fastest growing segment during the forecast period, 2023–2030.\u003c\/p\u003e\n\n\u003cp\u003eBased on end user, the US and Europe Metastases Spinal Tumor Market has been segmented into hospital \u0026amp; clinics, ambulatory surgery centers, research \u0026amp; academic institutes, and others.\u003c\/p\u003e\n\n\u003cp\u003eThe Europe metastases spinal tumor market held the largest market in 2022 with a market share of 51.32% and US is projected to be the fastest growing country during the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eMajor Players\u003cbr\u003e\nGE Healthcare (US), Medtronic Plc (Ireland), Amgen Inc (US), Siemens Healthineers AG (Germany), and Stryker (US), Merit Medical Systems (US), Brainlab AG (Germany), Johnson \u0026amp; Johnson Services Inc (US), Zimmer Biomet (US), and Shimadzu Corporation (Japan).\u003c\/p\u003e\n\n\u003cp\u003eCompanies Mentioned\u003cbr\u003e\nGE Healthcare (US)\u003cbr\u003e\nMedtronic Plc (Ireland)\u003cbr\u003e\nAmgen Inc (US)\u003cbr\u003e\nSiemens Healthineers AG (Germany)\u003cbr\u003e\nand Stryker (US)\u003cbr\u003e\nMerit Medical Systems (US)\u003cbr\u003e\nBrainlab AG (Germany)\u003cbr\u003e\nJohnson \u0026amp; Johnson Services Inc (US)\u003cbr\u003e\nZimmer Biomet (US)\u003cbr\u003e\nand Shimadzu Corporation (Japan).\u003c\/p\u003e\n\n\u003cp\u003ePlease note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"October, 2023 \/ 114 Pages \/ MCW16255840","offer_id":47650506342706,"sku":null,"price":3540.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/us-and-europe-metastases-spinal-tumor-market-research-report-forecast-to-2030","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}